U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07164027) titled 'Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial' on Aug. 25.
Brief Summary: This early phase I trial evaluates whether a new imaging technique using flotufolastat F 18 (a type of prostate specific membrane antigen [PSMA] imaging agent) with positron emission tomography (PET)/computed tomography (CT) can be used to guide targeted prostate biopsies in men with prostate cancer. Flotufolastat F 18 is a radioactive imaging agent that binds to prostate tumor cells that express PSMA. This allows for visualization of PSMA-expressing tumor cells on imaging scans such as PET/CT. PET is an established ima...